News
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
Medtronic has teamed up with Star Jones to get women talking about heart health. The TV personality is lending her star power ...
Get ready to rumble. In one corner, it’s President Donald Trump. In the other, it’s the pharmaceutical industry. | President ...
About a month after disclosing a $50 billion investment in its U.S. | Roche has earmarked more than $700 million to construct ...
Once again, AbbVie dominates doctors’ ranking of makers of immunology meds. | Just like last year, the Skyrizi and Rinvoq ...
A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...
Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...
On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...
In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...
Bristol Myers Squibb helmsman Chris Boerner joined a growing list of life sciences leaders announcing major U.S. investments ...
Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...
Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results